Glykon
News
PRESS RELEASES
• Glykon Invokes Patent Interference at the USPTO Against Alex Moffett, Parag Shah and Renaissance Herbs, Inc. for Hydroxycitrate (HCA) in Drug, Food and Beverage
• New Glykon Hydroxycitrate (HCA) Patent, Litigation against Renaissance Herbs Inc. and Alex Moffett
• Glykon Technologies Group Litigation Against Renaissance Herbs, Inc. and Its President, Alex S. Moffett
• Interhealth FASEB Presentation on Super Citrimax Hydroxycitrate (HCA) Confirms Glykon Patents
• Glykon Granted Hydroxycitric Acid (HCA) Blood Pressure Patent
• Hydroxicitrate (HCA) presentation at American
College of Nutrition meeting confirms Glykon
patents
• Study questions Super Citrimax appetite
reducing effect, supports Glykon Technologies patent
finding
• InterHealth Nutraceuticals Researchers Warn
Against HCA Lactone according to Glykon Technologies
Group
• (InterHealth Nutraceuticals
社が日本国立栄養健康研究所
(NIHN) のHCAの Lactone 毒性に関するレポートに反応)
• Renaissance Herbs, Glykon Cut Ties
• Glykon Technologies Group Ends HCA Licensing
Agreement with Renaissance Herbs
(The full text of these press releases is
reproduced below and in the linked file.)
August 22, 2006
LAS VEGAS, Aug /PRNewswire/ -- A new judge has been assigned in the lawsuit filed by Glykon Technologies Group LLC (Las Vegas, NV; http://www.glykon.com) against Renaissance Herbs, Inc. of Chatsworth, California and its president, Alex S. Moffett (also known as S. Alexander Moffett and Scott A. Moffett). Renaissance Herbs’ fully owned subsidiaries also potentially affected by the lawsuit are Ayurceutics (Chatsworth, California) and Dhanvantari Botanicals Pvt. Ltd. (India). The complaint was filed March 15, 2005 as Glykon Technologies Group, LLC v. Renaissance Herbs, Inc., et al. in Los Angeles Superior Court, Case No. BC 330334. The filing of litigation followed Glykon's termination on February 4, 2005 of a licensing agreement granting use of certain Glykon intellectual property to Renaissance Herbs, Inc. (“RHI”). Termination notice was published on the Natural Products Insider (NPI Center) internet site on March 2, 2005 and on the Natural Products Industry Insider website (In-The-News) on April 25, 2005. On April 11, 2005 RHI published a response on the NPI Center that failed to mention the active litigation, but notice of the Complaint can be found in the “Comments” thereto.
Inter alia, the Complaint alleges fraud, breach of contract, and failure to provide accounting either according to the ordinary terms of the contract or when specifically requested and required in response to termination. RHI, further, has attempted to misappropriate certain IP belonging to Glykon and made filings to the USPTO not fully listing the rightful inventors. Glykon is seeking Declaratory Relief, Accounting, and Rescission as well as punitive and exemplary damages. In addition to the current litigation, Glykon intends to pursue all those parties who knowingly aided and abetted RHI in its attempts to misappropriate Glykon IP, including any improper USPTO filing(s).
RHI failed to reveal before, during or after termination of the licensing agreement the results of safety tests where one or more hydroxycitric acid (HCA) products that it had supplied to Nippon Shinyaku of Japan had resulted in potentially serious toxicity findings. The home page of Japanese Ministry of Health and Labor Welfare (JMHLW) gives the first official announcement from the JMHLW dated on March 7th, 2002 describing toxicity findings based upon a product made by Renaissance Herbs and supplied to Nippon Shinyaku of Japan. The announcement is an interim report of a technical study dated on Feb. 4th, 2002 and can be found at the following web site (in Japanese): http://www.mhlw.go.jp/topics/2002/03/tp0307-1.html. A second and full finding of toxicity using a product manufactured by Renaissance Herbs for Nippon Shinyaku was published in January 2005 in the following article, although the data would have been available much earlier in Japan: Saito M, Ueno M, Ogino S, Kubo K, Nagata J, Takeuchi M. High dose of Garcinia cambogia is effective in suppressing fat accumulation in developing male Zucker obese rats, but highly toxic to the testis. Food Chem Toxicol. 2005 Mar;43(3):411-9. A full discussion of HCA safety as well as most of the Japan NIHN documents reporting the above-mentioned toxicity findings can be found via this link: http://www.glykon.com/page8/page8.html
RHI also failed to provide to Glykon important information regarding the company’s financial health. This information includes the fact that on February 13, 1997 the Van Nuys Municipal Court, LA County (CA) rendered a civil judgment (#96EO2325) against RHI for failure to pay debt. Likewise, RHI did not notify Glykon it had made a California UCC filing (#0327960047, filing date October 2, 2003).
RHI has been and continues to be the object of Food and Drug Administration (FDA) action and investigation. One open complaint focuses on resolving issues surround the toxicity reported in Japan with hydroxycitric acid products supplied by Renaissance Herbs. Queries for further information regarding FDA actions and investigations, including Complaint Number 31204, can be directed to:
U.S. Food and Drug Administration
Office of Information Resource Management
Division of Freedom of Information
5600 Fisher Lane
Rockville, MD 2058
Fax number: (301) 443-1726
Interhealth FASEB Presentation on Super Citrimax Hydroxycitrate (HCA) Confirms Glykon Patents
June 28, 2006
Las Vegas, NV, June 28, 2006 — At the Annual Meeting of the Federation of American Societies of Experimental
Biology (FASEB) (1), researchers confirmed Glykon patents on blood sugar regulation and insulin metabolism.
In genetically obese rats given Super CitriMax® (200 mg/kg/day in drinking water) or placebo for 6-7 weeks,
plasma insulin was reduced by 25% and insulin resistance by 16%. Previously at the 46th American College of
Nutrition Annual Meeting (2), Glykon presented research performed at Georgetown University Medical School
that showed effects of roughly twice this magnitude using only approximately 120 mg/kg/day of potassium and
potassium-magnesium hydroxycitrate. Potassium and potassium-magnesium HCA dramatically improved insulin
sensitivity and lowered serum insulin, but potassium-calcium HCA showed no such benefits at this lower
intake. The weaker showing of potassium-calcium HCA in most areas may be the result of limited assimilation
due to the presence of calcium and also the presence of the undesirable HCA lactone. Dutch scientists have
published similar results regarding potassium-calcium HCA and suggested that there are wide differences in
the physiologic benefits of the HCA salts being marketed. (3, 4)
Work from Europe based on Super CitriMax
previously had indicated a lack of benefit to insulin levels. (5) Glykon in US Patent 6,476,071 reported
that rats on a high fat diet received no weight control benefits from potassium-calcium HCA, whereas
potassium hydroxycitrate strongly reduced weight gain and insulin levels. Only Glykon holds the rights to
make claims regarding the impact of HCA on the regulation of insulin and blood sugar, modulation of leptin
and glucocorticoids, improvements in bone mineralization, the regulation of immune function, normalization
of blood pressure and control of inflammation. On February 4, 2005, Glykon terminated its licensing agreement
with Renaissance Herbs, Inc. covering uses and delivery systems for (–)-hydroxycitric acid and related
products.
(1) Asghar A, et al. Effect of a Novel Hydroxycitric Acid Extract (HCA-SX)...Annual Meeting of the Federation of American
Societies of Experimental Biology, Vol.20, No. 5, Abs. 655.4, Pg. 235, April 2006.
(2) Clouatre D, Preuss H, et al. Hydroxycitrate at Physiologic Levels Influences Insulin Sensitivity, Blood
Pressure and Inflammation in an Animal Model.
(3) Louter-van de Haar J, et al. Comparison of the effects of three different (–)-hydroxycitric acid preparations
on food intake in rats. Nutr Metab (Lond). 2005 Sep 13;2(1):23.
(4) Wielinga PY, et al. Hydroxycitric acid delays intestinal glucose absorption in rats. Am J Physiol Gastrointest Liver
Physiol. 2005 Jun;288(6):G1144-9.
(5) Leonhardt M, et al. Effect of hydroxycitrate on respiratory quotient, energy expenditure, and glucose tolerance
in male rats after a period of restrictive feeding. Nutrition. 2004 Oct;20(10):911-5.
Glykon Granted Hydroxycitric Acid (HCA) Blood Pressure Patent
March 21, 2006
Las Vegas, NV, March 21, 2006 —
The Unites States Patent and Trademark Office has granted to Glykon Technologies Group, LLC claims regarding the use of (–)-hydroxycitric acid, (–)-hydroxycitrate and HCA-related compounds for regulating blood pressure. Glykon now has six issued patents covering the use of HCA for insulin metabolism and blood sugar regulation (Syndrome X), regulation of glucocorticoids and leptin; bone mineralization and osteoporosis; wound healing and immune modulation.
The company also has patented multiple technologies greatly expanding the range of available delivery forms for HCA as well as improving its assimilation and activity. Glykon’s patent claims are now being confirmed by outside research. A presentation at the 46th American College of Nutrition Annual Meeting examined blood pressure, insulin levels and inflammation with the oral intake of three forms of hydroxycitrate (HCA) at doses resembling those used by humans. (1) All HCA forms significantly lowered blood pressure and trended towards reduced CRP and TNF-alpha, the potassium-magnesium HCA significantly. Potassium and potassium-magnesium HCA dramatically improved insulin sensitivity, but the potassium-calcium HCA showed no benefit. The weaker showing of potassium-calcium HCA in most areas may be the result of limited assimilation due to the presence of calcium and also the presence of the undesirable HCA lactone. Dutch scientists have published similar results regarding potassium-calcium HCA. (2) Differences in the quality of HCA salts on the market may be responsible for the inconsistent findings of researchers. (3) Researchers at InterHealth Nutraceuticals have indicated that findings of toxicity with a particular hydroxycitric acid product tested in Japan were due to the high amount of HCA lactone found in the item produced for Nippon Shinyaku by Renaissance Herbs, Inc. (4) Liquid HCA and HCA salts delivered in acidic beverages are characterized by elevated lactone levels.
Based in Las Vegas, Nevada, Glykon specializes in research, intellectual property development and licensing.
On February 4, 2005, Glykon terminated its licensing agreement with Renaissance Herbs, Inc. covering uses and delivery systems for (–)-hydroxycitric acid and related products.
*(1) Clouatre D, Preuss H, et al. Hydroxycitrate at Physiologic Levels Influences Insulin Sensitivity, Blood Pressure and Inflammation in an Animal Model.
(2) Louter-van de Haar J, et al. Comparison of the effects of three different (–)-hydroxycitric acid preparations on food intake in rats. Nutr Metab (Lond). 2005 Sep 13;2(1):23.
(3) Wielinga PY, et al. Hydroxycitric acid delays intestinal glucose absorption in rats. Am J Physiol Gastrointest Liver Physiol. 2005 Jun;288(6):G1144-9.
(4) Burdock G, et al. Garcinia cambogia toxicity is misleading. Food Chem Toxicol. 2005 Jun 30.
Hydroxicitrate (HCA)
presentation at American College of Nutrition meeting
confirms Glykon patents
November 5, 2005
Las Vegas, NV, November 5, 2005 — A presentation at
the 46th American College of Nutrition Annual Meeting
examined blood pressure, insulin levels and inflammation
with the oral intake of three forms of hydroxycitrate (HCA)
at doses resembling those used by humans. (1) All HCA forms
significantly lowered blood pressure and trended towards
reduced CRP and TNF-alpha, potassium-magnesium HCA
significantly. Potassium and potassium-magnesium HCA
dramatically improved insulin sensitivity, but the
potassium-calcium HCA showed no benefit. The weaker showing
of potassium-calcium HCA in most areas may be the result of
limited assimilation due to the presence of calcium and
also the presence of the undesirable HCA lactone. Dutch
scientists have published similar results regarding
potassium-calcium HCA. (2) Differences in the quality of
HCA salts on the market may be responsible for the
inconsistent findings of researchers. (3) Liquid HCA and
HCA salts delivered in acidic beverages are characterized
by elevated lactone levels.
Glykon Technologies Group, LLC has published similar
findings. In United States Patent 6,476,071, the company
reported that rats on a high fat diet received no weight
control benefits from potassium-calcium HCA, whereas
potassium hydroxycitrate strongly reduced weight gain. It
was found that more fully and properly reacted potassium
salts delivered greater benefits. William Matheny, a
partner at Glykon, affirms that the company produces only
fully reacted HCA salts. “We are committed to
efficacy. Our HCA products not only are fully reacted, but
also make use of special patented delivery systems to avoid
interaction with food and other ingredients.”
Glykon Technologies Group discovered and holds the rights
to make claims regarding the impact of HCA on the
regulation of insulin and blood sugar (Syndrome X),
modulation of leptin and glucocorticoids, improvements in
bone mineralization, the regulation of immune function,
normalization of blood pressure and control of
inflammation. The company also has patented multiple
technologies greatly expanding the range of available
delivery forms for HCA as well as improving its
assimilation and activity. Based in Las Vegas, Nevada,
Glykon specializes in research, intellectual property
development and licensing. On February 4, 2005, Glykon
terminated its licensing agreement with Renaissance Herbs,
Inc. covering uses and delivery systems for
(–)-hydroxycitric acid and related products.
(1) Clouatre D, Preuss H, et al. Hydroxycitrate at
Physiologic Levels Influences Insulin Sensitivity, Blood
Pressure and Inflammation in an Animal Model.
(2) Louter-van de Haar J, et al. Comparison of the effects
of three different (–)-hydroxycitric acid
preparations on food intake in rats. Nutr Metab (Lond).
2005 Sep 13;2(1):23.
(3) Wielinga PY, et al. Hydroxycitric acid delays
intestinal glucose absorption in rats. Am J Physiol
Gastrointest Liver Physiol. 2005 Jun;288(6):G1144-9.
Study
questions Super Citrimax appetite reducing effect, supports
Glykon Technologies patent finding
October 5, 2005
Las Vegas, NV, October 5, 2005 — Dutch researchers in
September 2005 (1) reported that InterHealth
Nutraceutical’s Super Citrimax potassium-calcium
hydroxycitric acid (HCA) salt performed poorly compared
with two other HCA samples, both of which were forms of
potassium hydroxycitrate. The scientists concluded that the
potassium hydroxycitrates “showed to be potent
inhibitors of food intake in rats, whereas Super Citrimax
HCA-600-SXS showed only small and more inconsistent
effects. The striking differences in efficacy between these
3 preparations indicate that low dosages of a relatively
low-effective HCA preparation may have contributed to the
lack of efficacy as found in several human studies.”
They suggested that the poor showing by Super Citrimax may
be the result of limited assimilation due to the presence
of calcium and also inactive and undesirable HCA lactone.
One of the researchers previously had indicated that
differences in the quality of HCA salts on the market are
responsible for inconsistent research findings. (2)
Glykon Technologies Group, LLC published similar research
as far back as 2002. In United States Patent 6,476,071
(Clouatre , et al. November 5, 2002, “Correcting
Polymorphic Metabolic Dysfunction with
(–)-Hydroxycitric Acid”), the company reported
that rats on a high fat diet received no weight control
benefits from potassium-calcium HCA, whereas potassium
hydroxycitrate strongly reduced weight gain. Several
potassium HCA salts were tested by Glykon. It was found
that the more fully and properly reacted the potassium
salt, the greater the benefits. William Matheny, a partner
at Glykon, affirms that the company produces only fully
reacted HCA salts. “We are committed to efficacy. Our
HCA products not only are fully reacted, but also make use
of special patented delivery systems to avoid interaction
with food and other ingredients.”
Glykon Technologies Group discovered and holds the rights
to make claims regarding the impact of HCA on the
regulation of insulin and blood sugar (Syndrome X),
modulation of leptin and glucocorticoids, improvements in
bone mineralization, the regulation of immune function, and
control of inflammation. The company also has patented
multiple technologies greatly expanding the range of
available delivery forms for HCA as well as improving its
assimilation and activity. Based in Las Vegas, Nevada,
Glykon specializes in research, intellectual property
development and licensing. On February 4, 2005, Glykon
terminated its licensing agreement with Renaissance Herbs,
Inc. covering uses and delivery systems for
(–)-hydroxycitric acid and related products.
(1) Louter-van de Haar J, et al. Comparison of the effects
of three different (-)-hydroxycitric acid preparations on
food intake in rats. Nutr Metab (Lond). 2005 Sep
13;2(1):23. (2) Wielinga PY, et al. Hydroxycitric acid
delays intestinal glucose absorption in rats. Am J Physiol
Gastrointest Liver Physiol. 2005 Jun;288(6):G1144-9
InterHealth Nutraceuticals Researchers
Warn Against HCA Lactone according to Glykon
Technologies Group
August 5, 2005
Las Vegas, NV, August 5, 2005 — In a letter(1)
published June 30, 2005 researchers at InterHealth
Nutraceuticals indicated that findings of toxicity with a
(–)-hydroxycitric acid product tested in Japan are
due to the high amount of HCA lactone found in the Japanese
item. The Japanese product was produced for Nippon Shinyaku
by Renaissance Herbs, Inc. of Chatsworth, California. At
high dosages, the Renaissance Herbs HCA in long-term animal
experiments led to a failure of the testicles to properly
develop. Trials with fully reacted HCA salts produced by
other companies have not shown any significant side effects
or toxicity, a point made by the InterHealth scientists.
Similar results of stunted testicular development were
discovered by Roche Pharmaceuticals approximately 35 years
ago in tests of the ethylenediamine salt of HCA. According
to Dallas Clouatre, Ph.D. author of The Diet and Health
Benefits of HCA (1994), “Researchers at Roche
concluded that the ethylenediamine HCA salt chelates the
mineral zinc from the system. Zinc is required for proper
testicular development and health. (–)-Hydroxycitric
acid in both its free acid and lactone forms is known to be
a powerful chelator of minerals. I argued against the
consumption of the free acid and lactone more than a decade
ago and all the major manufacturers of HCA were aware of
Roche’s experience. Therefore, I am somewhat
surprised that any company would have produced such a
product.”
The negative health findings implicating HCA free acid and
lactone pose problems for manufacturers of beverages
intended to include HCA as a functional ingredient. Even
fully reacted HCA salts slowly lactonize over time when
included in beverages, especially low pH (acid) beverages
and any beverage that has been pasteurized. Although there
may be little free acid or lactone present at the time of
manufacture, under normal conditions the lactone content of
drinks will usually increase significantly within a short
period.
Fully reacted HCA salts improve the mineral status of the
body, a finding that led to Glykon Technologies
Group’s US Patent No. 6,441,041. (www.glykon.com)
William Matheny, a partner at Glykon, affirms that the
company produces only fully reacted HCA salts. “We
are committed to efficacy. Our HCA products not only are
fully reacted, but also make use of special patented
delivery systems to avoid interaction with food and other
ingredients.”
(1) Burdock G, Bagchi M, Bagchi D. Garcinia cambogia
toxicity is misleading. Food Chem Toxicol. 2005 Jun 30.
This is a letter response to Saito M, et al. High dose of
Garcinia cambogia is effective in suppressing fat
accumulation in developing male Zucker obese rats, but
highly toxic to the testis. Food Chem Toxicol. 2005
Mar;43(3):411-9. These toxicity issues were first raised in
Japan in 2001 and 2002 in official Japanese government
findings, although the concerns have yet to be acknowledged
in the US by the companies involved.
Japanese Translation: InterHealth Nutraceuticals社が日本国立栄養健康研究所(NIHN)のHCAのLactone
毒性に関するレポートに反応
Natural
Products Industry Insider - News
Renaissance Herbs, Glykon Cut
Ties
Posted: April 25, 2005
LAS VEGAS—Glykon Technologies Group, based here,
announced it terminated its licensing agreement with
Renaissance Herbs, which covered uses and delivery systems
for (-)-hydroxycitric acid (HCA). The partnership was
announced in February 2004 and was terminated as of Feb. 4,
2005. Glykon holds a number of U.S. patents and patents
pending as well as proprietary technology relating to
HCA’s impact on insulin and blood sugar, bone
mineralization and immune function.
Copyright © 2005 by Virgo Publishing.
Natural
Products Insider Link
Glykon Technologies Group Ends HCA Licensing
Agreement with Renaissance Herbs
Posted: March 2, 2005
2005-03-22 - Glykon Technologies Group, LLC
Las Vegas, NV, March 21, 2005 — Glykon Technologies
Group, LLC has terminated its licensing agreement with
Renaissance Herbs, Inc. covering uses and delivery systems
for (–)-hydroxycitric acid and related products. The
effective date of the termination was February 4, 2005.
The agreement had incorporated 13 United States patents and
patents pending plus additional proprietary technology.
Glykon Technologies Group discovered and holds the rights
to make claims regarding the impact of HCA on the
regulation of insulin and blood sugar (Syndrome X),
modulation of leptin and glucocorticoids, improvements in
bone mineralization, the regulation of immune function, and
inflammation. The company also has patented multiple
technologies greatly expanding the range of available
delivery forms for HCA as well as improving its
assimilation and activity.
Glykon Technologies Group specializes in research,
intellectual property development and licensing. It is
based in Las Vegas, Nevada.
NPI Center Link